- Home
- TCBS vs AGEN Comparison
TCBS vs AGEN Comparison
Compare TCBS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBS
- AGEN
- Stock Information
- Founded
- TCBS 1934
- AGEN 1994
- Country
- TCBS United States
- AGEN United States
- Employees
- TCBS N/A
- AGEN N/A
- Industry
- TCBS Banks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCBS Finance
- AGEN Health Care
- Exchange
- TCBS Nasdaq
- AGEN Nasdaq
- Market Cap
- TCBS 44.9M
- AGEN 38.1M
- IPO Year
- TCBS N/A
- AGEN 2000
- Fundamental
- Price
- TCBS $15.11
- AGEN $2.87
- Analyst Decision
- TCBS
- AGEN Buy
- Analyst Count
- TCBS 0
- AGEN 4
- Target Price
- TCBS N/A
- AGEN $8.00
- AVG Volume (30 Days)
- TCBS 1.9K
- AGEN 655.0K
- Earning Date
- TCBS 05-13-2025
- AGEN 05-06-2025
- Dividend Yield
- TCBS 1.06%
- AGEN N/A
- EPS Growth
- TCBS N/A
- AGEN N/A
- EPS
- TCBS N/A
- AGEN N/A
- Revenue
- TCBS $10,489,000.00
- AGEN $103,463,000.00
- Revenue This Year
- TCBS N/A
- AGEN $4.03
- Revenue Next Year
- TCBS N/A
- AGEN $5.57
- P/E Ratio
- TCBS N/A
- AGEN N/A
- Revenue Growth
- TCBS N/A
- AGEN N/A
- 52 Week Low
- TCBS $13.51
- AGEN $1.38
- 52 Week High
- TCBS $17.50
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- TCBS 31.27
- AGEN 73.11
- Support Level
- TCBS $15.60
- AGEN $1.60
- Resistance Level
- TCBS $16.20
- AGEN $1.83
- Average True Range (ATR)
- TCBS 0.12
- AGEN 0.29
- MACD
- TCBS -0.08
- AGEN 0.15
- Stochastic Oscillator
- TCBS 8.05
- AGEN 77.60
About TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).